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OBJECTIVES: Surgical techniques including sentinel lymph node biopsy (SLNB) and
4-node sampling (4-NS) are currently used for axillary nodal assessment of early
breast cancer (EBC) in the UK. Such procedures are associated with adverse effects,
(AEs), in particular scarring, pain, general anaesthesia and occasional lymphoe-
dema which may impact on long term quality of life. Magnetic resonance imaging
(MRI) is a non-invasive technique offering the potential to avoid such AEs. A range
of MRI techniques, including USPIO (ultrasmall superparamagnetic iron oxide con-
trast agent)-enhanced and gadolinium-enhanced MRI exist, however diagnostic
accuracy of these techniques may be lower than for surgical techniques. An eco-
nomic evaluation was undertaken to compare MRI with surgical techniques for
assessment of axillary lymph node metastases in patients with EBC. METHODS:
The costs and benefits of replacing SLNB or 4-NS with MRI (replacement strategy) or
adding MRI before the surgical techniques (addition strategy) were modelled using
discrete-event simulation in SIMUL8®. A systematic review was undertaken to
obtain effectiveness outcomes of the MRI techniques, whilst resource use data and
health related utilities were obtained from the literature. RESULTS: Our results
predict that a replacement strategy for MRI, based on the pooled estimate of all MRI
techniques, dominates the baseline SLNB and 4-NS strategies, as a result of avoid-
ing AEs from surgical techniques. However this strategy leads to more false-posi-
tive and false-negative cases. The MRI addition strategy may also be cost-effective,
but is subject to greater uncertainty. USPIO-enhanced MRI produces the most fa-
vourable cost effectiveness ratio, but the evidence is based on studies with small
patient numbers. CONCLUSIONS: These results suggest that there is a potential
role for MRI in axillary node assessment of EBC. Based on current evidence USPIO-
enhanced MRI offers the most cost effective option, but further large studies are
required to obtain high quality evidence on diagnostic accuracy.
PMD50
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OBJECTIVES:To assess the cost-effectiveness of cardiac resynchronisation therapy
(CRT) both with CRT-P (biventricular pacemaker only) and CRT-D (biventricular
pacemaker with defibrillator) in patients with New York Heart Association (NYHA)
functional class III/IV from a Belgian health care payer perspective. METHODS: A
lifetime Markov model was designed to calculate the cost-utility of both interven-
tions. In the reference case, the treatment effect is based on the COMPANION trial.
Costs are based on real-world data. Pharmacoeconomic guidelines were applied,
including probabilistic modelling and sensitivity analyses. RESULTS: Compared
with optimal medical treatment, on average 1.31 quality-adjusted life-years (QALY)
are gained with CRT-P at an additional cost of €14,700, resulting in an incremental
cost-effectiveness ratio (ICER) of about €11,200/QALY. As compared to CRT-P,
CRT-D treatment adds on average an additional 0.55 QALYs at an extra cost of
€30,900 resulting in an ICER of €57,000/QALY. This result was very sensitive to the
incremental clinical benefit of the defibrillator function on top of CRT.
CONCLUSIONS: Based on efficiency arguments, CRT-P can be recommended for
NYHA class III and IV patients if there is a willingness to pay more than €11,000/
QALY. Even though CRT-D may offer a survival benefit over CRT-P, the incremental
clinical benefit appears to be too marginal to warrant a three times higher device
price for CRT-D. Further clinical research should focus on the added value of CRT-D
over CRT-P.
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OBJECTIVES: Early diagnosis of Alzheimer’s disease may allow for early appropri-
ate treatment, delayed symptom aggravation, delayed nursing home placement,
and reduced care costs. The use of Amyloid-specific Positron Emission Tomogra-
phy (PET) scanning might complement routine clinical diagnostic procedures and
lead to earlier and more accurate differential diagnosis than presently possible.
The aim of this study is to estimate cost-effectiveness of Florbetaben PET imaging.
METHODS: A decision-analytic model using Markov cohorts to simulate Alzhei-
mer’s disease (AD) management compares, from a societal perspective, three strat-
egies after routine clinical assessment: 1) use of Florbetaben PET to direct treat-
ment decisions; 2) “treat all” approach; 3) “wait and see” approach. RESULTS:
Florbetaben PET appears to be cost-effective and strictly dominant: both compar-
ator strategies result in higher long-term costs at lower health outcomes. Values of
incremental costs saved (US$2340 – without considering cost of Florbetaben tracer)
and health outcomes gained (0.028 QALYs) to the nearest comparator strategy are
small. However, the results prove to be robust in sensitivity analyses.
CONCLUSIONS: Although Florbetaben PET imaging has significant upfront costs,
identifying and treating patients with AD early and correctly results in overall cost
savings and QALYs gained. This analysis may underestimate the true benefit of
Florbetaben PET imaging because the value of knowing early about the underlying
pathology from the perspective of patients and caregivers is not implemented in
the model – apart from medical and economic value, even emotional aspects and
the opportunity for future planning should be considered. This could be subject of
further research.
PMD52
WORKLOAD IN GERMAN HOSPITALS CAUSED BY ROUTINE FOLLOW-UP
SERVICES FOR CARDIAC IMPLANTABLE ELECTRICAL DEVICES (CIED)
Smala A1, Vogtmann T2
1Biotronik SE & Co KG, Global Reimbursement and Health Economics, Berlin, Germany,
2Kardiologische Gemeinschaftspraxis “Am Park Sanssouci”, Potsdam, Germany
OBJECTIVES: Regular follow-up (FU) of CIED patients is mandatory to monitor de-
vice functionality and disease status. Demand for this highly specialised service
increases continuously. However, most calendar based visits do not need further
action and could safely be replaced by remote monitoring. This model aims 1) to
quantify hospital workload associated with calendar based FU between 2011 and
2015, and 2) to identify opportunity costs if monitoring services would be per-
formed remotely. METHODS: The estimated number of prevalent CIED patients in
Germany was combined with recently published data on healthcare personnel
resource burden related to FU. Opportunity costs were identified considering 2011
DRG payments for frequent cardiology procedures. RESULTS: Assuming in-office
FU twice annually for pacemaker patients, and four times annually for implantable
cardioverter defibrillator or cardiac resynchronisation therapy patients, hospitals
will have to provide about 2.23 mio FU services in 2015, to about 856,000 patients.
These services will bind about 411,000 physician hours, 392,000 nurse hours and
280,000 technician hours, at total costs of EURO 44.8 mio to hospitals. Using remote
monitoring to replace all but one in-office FU visit per year could free up to 126,700
physician hours (2015). In theory, this physician time would allow for about 50’600
bypass surgeries (worth EURO 596 mio), or 84,400 dual-chamber pacemaker im-
plantations (EURO 434 mio), or 63,300 dual chamber ICD implantations (EURO 1.1
billion). Possible cost overestimation due to not considering unscheduled FU visits
is explored in scenario analyses. CONCLUSIONS: The ability of BIOTRONIK Home
Monitoring to safely replace in-office FU visits has been proven in clinical trials.
While continuously monitoring all patients, it is possible to identify patients in
need to attend in clinic FU in person. Remote monitoring technologies can support
hospitals with focussing their available staff and room capacities and optimise
operative income while providing patient care at potentially improved outcomes.
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OBJECTIVES: Electrical Pulmonary Vein (PV) Isolation (PVI) is regarded as effective
treatment of Symptomatic Drug-Refractory Paroxysmal Atrial Fibrillation (PAF).
Traditionally, appropriate circumferential lesions were created point-by-point, us-
ing single tip catheters guided by navigation systems, and generally employing
radiofrequency (RF) source. “Anatomically-Designed” catheters were introduced
recently and are pre-shaped to create the appropriate lesions with a single appli-
cation on each PV. We hypothesised that the shape of these catheters is associated
with reduced procedure times and Operating Room (OR) productivity gains. In this
study, catheters employing cryo (Arctic Front, Medtronic) and duty cycled bipolar
radiofrequency (PVAC, Medtronic) energy sources were examined. METHODS: Us-
ing a chart review approach, 158 procedures were included (85 with “anatomically-
designed” catheters, 73 “point-by point”) across 7 diversified French centres. Selec-
tion criteria were used to ensure comparability of procedures. In parallel an
economic analysis was performed to estimate the budgetary impact in terms of
DRG case-mix for hospitals, resulting from potential increased OR activity.
RESULTS: Reduced procedure time was observed in six out of seven participating
centres. The difference in median times was 35 minutes (p0.0192). There was
significant variability of procedures times depending on hospital status (public or
private), the experience of electrophysiologists involved and the annual activity.
Based on the DRG casemix produced in the rythmology OR and the current tariffs,
the mean revenue for the centre was estimated between 1100€ (private) and, 400 €
(public) per hour of total OR time. CONCLUSIONS: Use of “Anatomically-Designed”
PVI Catheters has the potential to substantially reduce procedure time and in-
crease procedure capacity of rythmology labs. Shorter procedure times allow better
management of OR and treatment of more patients with potential productivity
gains to hospitals that may offset the extra cost of the new techniques.
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TRACT INFECTIONS IN SWEDISH SPINAL INJURY PATIENTS
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OBJECTIVES: To collect real-life data on costs and resource use, in order to under-
stand the economic burden and treatment patterns of urinary tract infection (UTI)
amongst people with spinal injury, who are in need of chronic, intermittent
catheterisation. METHODS: We used the CEBRxA database, which combines data
from a public claims database for the South-West region of Sweden, comprising
around 1.5 million individuals, with national Swedish registers on drug utilisation
and mortality. We identified a population of spinal injury patients (ICD-10 S14.0,
S24.0, S34.0, and T91.31) who in addition had received a diagnosis of neurogenic
bladder (ICD-10 N31*), anytime during the years 2000 to 2009. UTIs were identified
through the following ICD-10 codes: N11.0, N30*, N39.0*, N39.X*, N12.-P, and N30.-P.
A cost per UTI was calculated through considering UTI-related care contacts that
occurred within 14 days from each other (from 2005-07-01 onwards). RESULTS:We
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